Equity Profile

SNY

Sanofi

Health CarePharmaceuticals$105.3B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2012Pre-Market9:00 AM EDT

Company Snapshot

Sanofi (SNY) is a global healthcare company focused on pharmaceuticals and vaccines. With a market cap of $105 billion, it plays a crucial role in developing treatments for various diseases, making it significant in the healthcare sector.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

Estimates not available

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, which is vital for long-term success.

Estimates not available

Wall Street expectations, options signals, track record, and call prep available with Pro.

SNY Q2-2012 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+120.71%

Avg Stock Reaction

+1.51%

Last Quarter Recap

In Q1-2012, Sanofi reported an EPS of $2.45, significantly beating expectations by 116.64%. The stock reacted positively, increasing by 2.28% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Sanofi's upcoming earnings are uncertain, given the lack of analyst estimates. However, the company has a strong track record of beating EPS estimates.

Bull Case

If Sanofi continues its trend of beating EPS estimates, it could see a positive stock reaction, especially if revenue growth is also strong.

Bear Case

On the other hand, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative reaction from investors.

Key Metrics to Watch

Earnings Per Share (EPS)

Estimates not available

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

Revenue Growth

Estimates not available

Revenue growth reflects the company's ability to increase sales and expand its market presence, which is vital for long-term success.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for this quarter?

Given Sanofi's strong history of beating EPS estimates, the market will closely watch this figure to gauge the company's performance.

How is revenue growth trending?

Revenue growth is crucial for assessing the company's future prospects and market position, making it a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Sanofi's ability to maintain strong EPS growth despite market pressures, given its historical performance.

Supporting Evidence

Sanofi has consistently beaten EPS estimates in the past, suggesting a strong operational foundation.

The options market indicates low expected volatility, which may not reflect the company's potential for a positive surprise.

Key Risk

If the EPS comes in below $2.00, it could challenge the current positive sentiment around the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to maintain its strong earnings trajectory amid market challenges.

Bull Confirmed If

An EPS of $2.50 or higher would confirm the bull case and suggest strong financial health.

Bear Confirmed If

An EPS below $2.00 would support the bear case, indicating potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±1.28%

Historical Avg

±3.1%

Pricing cheap

The options market is pricing a relatively small move for Sanofi's stock, indicating that investors may not expect significant volatility around the earnings report.

Options are pricing ±1.3% while SNY has averaged ±3.1% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.3%

30d HV

25.3%

Calls (55K)P/C Ratio: 0.34Puts (44K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sanofi beats expectations, history suggests the stock could rise by about 1.51% on the first day after the earnings report.

In-Line / Cautious

If the results are in line with expectations, the stock may experience a muted reaction as investors assess future guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 1.51%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or pipeline developments.
2Insights into revenue growth from key product lines.
3Management's commentary on market challenges and competitive landscape.
4Guidance on future earnings expectations and strategic initiatives.
5Any changes in operational efficiency or cost management strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

Estimates not available

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, which is vital for long-term success.

Estimates not available

Wall Street expectations, options signals, track record, and call prep available with Pro.

SNY Q2-2012 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+120.71%

Avg Stock Reaction

+1.51%

Last Quarter Recap

In Q1-2012, Sanofi reported an EPS of $2.45, significantly beating expectations by 116.64%. The stock reacted positively, increasing by 2.28% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Sanofi's upcoming earnings are uncertain, given the lack of analyst estimates. However, the company has a strong track record of beating EPS estimates.

Bull Case

If Sanofi continues its trend of beating EPS estimates, it could see a positive stock reaction, especially if revenue growth is also strong.

Bear Case

On the other hand, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative reaction from investors.

Key Metrics to Watch

Earnings Per Share (EPS)

Estimates not available

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

Revenue Growth

Estimates not available

Revenue growth reflects the company's ability to increase sales and expand its market presence, which is vital for long-term success.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for this quarter?

Given Sanofi's strong history of beating EPS estimates, the market will closely watch this figure to gauge the company's performance.

How is revenue growth trending?

Revenue growth is crucial for assessing the company's future prospects and market position, making it a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Sanofi's ability to maintain strong EPS growth despite market pressures, given its historical performance.

Supporting Evidence

Sanofi has consistently beaten EPS estimates in the past, suggesting a strong operational foundation.

The options market indicates low expected volatility, which may not reflect the company's potential for a positive surprise.

Key Risk

If the EPS comes in below $2.00, it could challenge the current positive sentiment around the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to maintain its strong earnings trajectory amid market challenges.

Bull Confirmed If

An EPS of $2.50 or higher would confirm the bull case and suggest strong financial health.

Bear Confirmed If

An EPS below $2.00 would support the bear case, indicating potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±1.28%

Historical Avg

±3.1%

Pricing cheap

The options market is pricing a relatively small move for Sanofi's stock, indicating that investors may not expect significant volatility around the earnings report.

Options are pricing ±1.3% while SNY has averaged ±3.1% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.3%

30d HV

25.3%

Calls (55K)P/C Ratio: 0.34Puts (44K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sanofi beats expectations, history suggests the stock could rise by about 1.51% on the first day after the earnings report.

In-Line / Cautious

If the results are in line with expectations, the stock may experience a muted reaction as investors assess future guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 1.51%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or pipeline developments.
2Insights into revenue growth from key product lines.
3Management's commentary on market challenges and competitive landscape.
4Guidance on future earnings expectations and strategic initiatives.
5Any changes in operational efficiency or cost management strategies.